A Real-World Study on Extranodal Lymphoma
NCT06573099 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000
Last updated 2024-08-27
Summary
The aim of this study is to prospectively collect clinical information on patients with extranodal lymphoma, and to explore the best therapeutic strategies in the real-world population.
Conditions
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Extranodal Lymphoma
- Diffuse Large B Cell Lymphoma
Interventions
- OTHER
-
No interventions need to be specified for this study
No interventions need to be specified for this study
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-09-01
- Primary Completion
- 2027-09-01
- Completion
- 2029-09-01
More Related Trials
-
ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma
NCT06149390 ·Status: COMPLETED
-
Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas
NCT03985696 ·Status: UNKNOWN ·Phase: NA
-
Frontline of ASCT in High-risk DLBCL
NCT05831865 ·Status: RECRUITING
-
A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma
NCT04434833 ·Status: UNKNOWN
-
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
NCT05290090 ·Status: RECRUITING ·Phase: PHASE2
-
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05189782 ·Status: UNKNOWN
-
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
NCT05164770 ·Status: UNKNOWN ·Phase: PHASE3
-
A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission
NCT05874778 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
NCT05777369 ·Status: UNKNOWN ·Phase: NA
-
A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
NCT04923789 ·Status: UNKNOWN
-
Obinutuzumab in Chinese Real-world Patients With iNHL
NCT05968001 ·Status: NOT_YET_RECRUITING
-
On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma
NCT06503211 ·Status: RECRUITING ·Phase: PHASE1
-
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
NCT05883709 ·Status: UNKNOWN
-
MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma
NCT02399189 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT02957019 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
NCT05557903 ·Status: UNKNOWN ·Phase: PHASE1
-
Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT05338892 ·Status: COMPLETED
-
Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL
NCT07059741 ·Status: RECRUITING ·Phase: NA
-
A Combination Study of CAR-T Therapy in r/r B-NHL
NCT05871684 ·Status: UNKNOWN ·Phase: PHASE2
-
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
NCT05821192 ·Status: UNKNOWN ·Phase: NA
-
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT00720135 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma
NCT04934579 ·Status: COMPLETED ·Phase: PHASE2
-
Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas
NCT00685997 ·Status: COMPLETED
-
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
NCT05690191 ·Status: ENROLLING_BY_INVITATION
-
Decitabine and Anti-PD-1 in R/R DLBCL
NCT05816746 ·Status: RECRUITING ·Phase: PHASE2